Oppenheimer lowered the firm’s price target on Evolent Health (EVH) to $28 from $34 and keeps an Outperform rating on the shares. The firm hosted meetings with management and believes the company is positioned to recover from trough Q4 levels. Management is actively weighing shifts to the fee-based model in cases where profitability is no longer possible, but is optimistic it can leverage up to $100M of expected price increases to unlock higher baseline EBITDA.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health management to meet with Oppenheimer
- Evolent Health price target lowered to $21 from $33 at Citi
- Evolent Health price target lowered to $19 from $39 at Barclays
- Evolent Health price target lowered to $20 from $42 at RBC Capital
- Evolent Health price target lowered to $36 from $45 at BTIG